Table of Contents Author Guidelines Submit a Manuscript
BioMed Research International
Volume 2015, Article ID 465342, 13 pages
http://dx.doi.org/10.1155/2015/465342
Research Article

An Upgrade on the Rabbit Model of Anthracycline-Induced Cardiomyopathy: Shorter Protocol, Reduced Mortality, and Higher Incidence of Overt Dilated Cardiomyopathy

1Departamento de Medicina y Cirugía Animal, Facultad de Veterinaria, Universidad de Murcia, Campus de Excelencia Internacional Regional “Campus Mare Nostrum”, 30100 Murcia, Spain
2School of Biological Sciences, Institute for Cardiovascular and Metabolic Research, University of Reading, Reading RG6 6AS, UK
3Departamento de Anatomía y Anatomía Comparada, Facultad de Veterinaria, Universidad de Murcia, Campus de Excelencia Internacional Regional “Campus Mare Nostrum”, 30100 Murcia, Spain
4Institute of Virology and Immunology (IVI), Sensemattstrasse 293, 3147 Mittelhäusern, Switzerland
5Unidad de Trasplante Hematopoyético y Terapia Celular, Departamento de Hematología, Hospital Universitario Virgen de la Arrixaca, IMIB, Universidad de Murcia, 30120 Murcia, Spain

Received 21 August 2015; Revised 24 November 2015; Accepted 26 November 2015

Academic Editor: Peter M. Becher

Copyright © 2015 Jesús Talavera et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. G. Minotti, P. Menna, E. Salvatorelli, G. Cairo, and L. Gianni, “Anthracyclines: molecular advances and pharmacologic developments in antitumor activity and cardiotoxicity,” Pharmacological Reviews, vol. 56, no. 2, pp. 185–229, 2004. View at Publisher · View at Google Scholar · View at Scopus
  2. P. K. Singal and N. Iliskovic, “Doxorubicin-induced cardiomyopathy,” The New England Journal of Medicine, vol. 339, no. 13, pp. 900–905, 1998. View at Publisher · View at Google Scholar · View at Scopus
  3. J. R. Carver, C. L. Shapiro, A. Ng et al., “American society of clinical oncology clinical evidence review on the ongoing care of adult cancer survivors: cardiac and pulmonary late effects,” Journal of Clinical Oncology, vol. 25, no. 25, pp. 3991–4008, 2007. View at Publisher · View at Google Scholar · View at Scopus
  4. A. Verdecchia, S. Francisci, H. Brenner et al., “Recent cancer survival in Europe: a 2000-02 period analysis of EUROCARE-4 data,” The Lancet Oncology, vol. 8, no. 9, pp. 784–796, 2007. View at Publisher · View at Google Scholar · View at Scopus
  5. S. M. Pogwizd and D. M. Bers, “Rabbit models of heart disease,” Drug Discovery Today: Disease Models, vol. 5, no. 3, pp. 185–193, 2008. View at Publisher · View at Google Scholar · View at Scopus
  6. R. Maral, G. Bourat, R. Ducrot et al., “Toxicologic study and experimental antitumor activity of rubidomycin,” Pathologie et Biologie, vol. 15, pp. 903–908, 1967. View at Google Scholar
  7. R. S. Jaenke, “Delayed and progressive myocardial lesions after adriamycin administration in the rabbit,” Cancer Research, vol. 36, no. 8, pp. 2958–2966, 1976. View at Google Scholar · View at Scopus
  8. E. H. Herman, V. J. Ferrans, W. Jordan, and B. Ardalan, “Reduction of chronic daunorubicin cardiotoxicity by ICRF-187 in rabbits,” Research Communications in Chemical Pathology and Pharmacology, vol. 31, no. 1, pp. 85–97, 1981. View at Google Scholar · View at Scopus
  9. E. H. Herman and V. J. Ferrans, “Pretreatment with ICRF-187 provides long-lasting protection against chronic daunorubicin cardiotoxicity in rabbits,” Cancer Chemotherapy and Pharmacology, vol. 16, no. 2, pp. 102–106, 1986. View at Google Scholar · View at Scopus
  10. T. Šimůnek, I. Klimtová, J. Kaplanová et al., “Rabbit model for in vivo study of anthracycline-induced heart failure and for the evaluation of protective agents,” European Journal of Heart Failure, vol. 6, no. 4, pp. 377–387, 2004. View at Publisher · View at Google Scholar
  11. O. Popelová, M. Sterba, P. Haková et al., “Dexrazoxane-afforded protection against chronic anthracycline cardiotoxicity in vivo: effective rescue of cardiomyocytes from apoptotic cell death,” British Journal of Cancer, vol. 101, no. 5, pp. 792–802, 2009. View at Publisher · View at Google Scholar · View at Scopus
  12. O. Popelova, M. Sterba, T. Simunek et al., “Deferiprone does not protect against chronic anthracycline cardiotoxicity in vivo,” Journal of Pharmacology and Experimental Therapeutics, vol. 326, no. 1, pp. 259–269, 2008. View at Publisher · View at Google Scholar
  13. A. Vávrová, O. Popelová, M. Štěrba et al., “In vivo and in vitro assessment of the role of glutathione antioxidant system in anthracycline-induced cardiotoxicity,” Archives of Toxicology, vol. 85, no. 5, pp. 525–535, 2011. View at Publisher · View at Google Scholar · View at Scopus
  14. M. Chen, Z.-C. Fan, X.-J. Liu et al., “Effects of autologous stem cell transplantation on ventricular electrophysiology in doxorubicin-induced heart failure,” Cell Biology International, vol. 30, no. 7, pp. 576–582, 2006. View at Publisher · View at Google Scholar · View at Scopus
  15. F. N. Gava, E. Zacché, E. M. G. Ortiz et al., “Doxorubicin induced dilated cardiomyopathy in a rabbit model: an update,” Research in Veterinary Science, vol. 94, no. 1, pp. 115–121, 2013. View at Publisher · View at Google Scholar · View at Scopus
  16. N. Engberding, S. Spiekermann, A. Schaefer et al., “Allopurinol attenuates left ventricular remodeling and dysfunction after experimental myocardial infarction: a new action for an old drug?” Circulation, vol. 110, no. 15, pp. 2175–2179, 2004. View at Publisher · View at Google Scholar · View at Scopus
  17. D. Deprez-DeCampeneere, R. Jaenke, and A. Trouet, “Comparative cardiac and renal toxicity of daunorubicin in the rat and rabbit,” Cancer Treatment Reports, vol. 66, no. 2, pp. 395–397, 1982. View at Google Scholar · View at Scopus
  18. E. H. Herman and V. J. Ferrans, “Preclinical animal models of cardiac protection from anthracycline-induced cardiotoxicity,” Seminars in Oncology, vol. 25, no. 4, pp. 15–21, 1998. View at Google Scholar · View at Scopus
  19. I. Klimtová, T. Šimůnek, Y. Mazurová, R. Hrdina, V. Geršl, and M. Adamcová, “Comparative study of chronic toxic effects of daunorubicin and doxorubicin in rabbits,” Human & Experimental Toxicology, vol. 21, no. 12, pp. 649–657, 2002. View at Publisher · View at Google Scholar · View at Scopus
  20. J. F. Van Vleet and V. J. Ferrans, “Clinical and pathologic features of chronic adriamycin toxicosis in rabbits,” American Journal of Veterinary Research, vol. 41, no. 9, pp. 1462–1469, 1980. View at Google Scholar · View at Scopus
  21. S. M. Swain, F. S. Whaley, and M. S. Ewer, “Congestive heart failure in patients treated with doxorubicin,” Cancer, vol. 97, no. 11, pp. 2869–2879, 2003. View at Publisher · View at Google Scholar · View at Scopus
  22. D. J. Sahn, A. DeMaria, J. Kisslo, and A. Weyman, “Recommendations regarding quantitation in M-mode echocardiography: results of a survey of echocardiographic measurements,” Circulation, vol. 58, no. 6, pp. 1072–1083, 1978. View at Publisher · View at Google Scholar · View at Scopus
  23. W. P. Thomas, C. E. Gaber, G. J. Jacobs et al., “Recommendations for standards in transthoracic two-dimensional echocardiography in the dog and cat. Echocardiography Committee of the Specialty of Cardiology, American College of Veterinary Internal Medicine,” Journal of Veterinary Internal Medicine, vol. 7, no. 4, pp. 247–252, 1993. View at Google Scholar
  24. K. E. Quesenberry, Saunders Manual of Small Animal Practice, W.B. Saunders Company, Philadelphia, Pa, USA, 1994.
  25. L. Gianni, E. H. Herman, S. E. Lipshultz, G. Minotti, N. Sarvazyan, and D. B. Sawyer, “Anthracycline cardiotoxicity: from bench to bedside,” Journal of Clinical Oncology, vol. 26, no. 22, pp. 3777–3784, 2008. View at Publisher · View at Google Scholar · View at Scopus
  26. S. Okuda, Y. Oh, H. Tsuruda, K. Onoyama, S. Fujimi, and M. Fujishima, “Adriamycin-induced nephropathy as a model of chronic progressive glomerular disease,” Kidney International, vol. 29, no. 2, pp. 502–510, 1986. View at Publisher · View at Google Scholar · View at Scopus
  27. H.-F. Liu, L.-Q. Guo, Y.-Y. Huang et al., “Thiazolidinedione attenuate proteinuria and glomerulosclerosis in Adriamycin-induced nephropathy rats via slit diaphragm protection,” Nephrology, vol. 15, no. 1, pp. 75–83, 2010. View at Publisher · View at Google Scholar · View at Scopus
  28. O. A. Badary, A. B. Abdel-Naim, M. H. Abdel-Wahab, and F. M. A. Hamada, “The influence of thymoquinone on doxorubicin-induced hyperlipidemic nephropathy in rats,” Toxicology, vol. 143, no. 3, pp. 219–226, 2000. View at Publisher · View at Google Scholar · View at Scopus
  29. N. R. Bachur, R. C. Hildebrand, and R. S. Jaenke, “Adriamycin and daunorubicin disposition in the rabbit,” Journal of Pharmacology and Experimental Therapeutics, vol. 191, no. 2, pp. 331–340, 1974. View at Google Scholar · View at Scopus
  30. S. L. Curry, H. B. Muss, J. A. Blessing, and J. Arseneau, “Hematologic monitoring in patients with cancer. A study of the Gynecologic Oncology Group,” American Journal of Clinical Oncology, vol. 10, no. 2, pp. 163–166, 1987. View at Google Scholar · View at Scopus
  31. G. Falkson, B. Klein, and H. Falkson, “Hematological toxicity: experience with anthracyclines and anthracenes,” Experimental Hematology, vol. 13, supplement 16, pp. 64–71, 1985. View at Google Scholar · View at Scopus
  32. J. N. Barreto, K. B. McCullough, L. L. Ice, and J. A. Smith, “Antineoplastic agents and the associated myelosuppressive effects: a review,” Journal of Pharmacy Practice, vol. 27, no. 5, pp. 440–446, 2014. View at Publisher · View at Google Scholar · View at Scopus
  33. M. Štěrba, O. Popelová, J. Lenčo et al., “Proteomic insights into chronic anthracycline cardiotoxicity,” Journal of Molecular and Cellular Cardiology, vol. 50, no. 5, pp. 849–862, 2011. View at Publisher · View at Google Scholar
  34. P. P. Liu, “Cardiorenal syndrome in heart failure: a cardiologist's perspective,” Canadian Journal of Cardiology, vol. 24, supplement B, pp. 25B–29B, 2008. View at Publisher · View at Google Scholar · View at Scopus
  35. S. E. Lipshultz, S. R. Lipsitz, S. M. Mone et al., “Female sex and higher drug dose as risk factors for late cardiotoxic effects of doxorubicin therapy for childhood cancer,” The New England Journal of Medicine, vol. 332, no. 26, pp. 1738–1743, 1995. View at Publisher · View at Google Scholar · View at Scopus
  36. M. Amigoni, C. Giannattasio, D. Fraschini et al., “Low anthracyclines doses-induced cardiotoxicity in acute lymphoblastic leukemia long-term female survivors,” Pediatric Blood & Cancer, vol. 55, no. 7, pp. 1343–1347, 2010. View at Publisher · View at Google Scholar · View at Scopus
  37. O. Hequet, Q. H. Le, I. Moullet et al., “Subclinical late cardiomyopathy after doxorubicin therapy for lymphoma in adults,” Journal of Clinical Oncology, vol. 22, no. 10, pp. 1864–1871, 2004. View at Publisher · View at Google Scholar · View at Scopus
  38. J. Zhang, A. Knapton, S. E. Lipshultz, T. R. Cochran, H. Hiraragi, and E. H. Herman, “Sex-related differences in mast cell activity and doxorubicin toxicity: a study in spontaneously hypertensive rats,” Toxicologic Pathology, vol. 42, no. 2, pp. 361–375, 2014. View at Publisher · View at Google Scholar · View at Scopus
  39. M. M. Freeland, J. Angulo, A. L. Davis et al., “Sex differences in improved efficacy of doxorubicin chemotherapy in Cbr1+/− mice,” Anti-Cancer Drugs, vol. 23, no. 6, pp. 584–589, 2012. View at Publisher · View at Google Scholar · View at Scopus
  40. M. Moulin, J. Piquereau, P. Mateo et al., “Sexual dimorphism of doxorubicin-mediated cardiotoxicity: potential role of energy metabolism remodeling,” Circulation: Heart Failure, vol. 8, no. 1, pp. 98–108, 2015. View at Publisher · View at Google Scholar
  41. M. Lotrionte, G. Biondi-Zoccai, A. Abbate et al., “Review and meta-analysis of incidence and clinical predictors of anthracycline cardiotoxicity,” The American Journal of Cardiology, vol. 112, no. 12, pp. 1980–1984, 2013. View at Publisher · View at Google Scholar · View at Scopus
  42. J. G. Blanco, C.-L. Sun, W. Landier et al., “Anthracycline-related cardiomyopathy after childhood cancer: role of polymorphisms in carbonyl reductase genes—a report from the Children's Oncology Group,” Journal of Clinical Oncology, vol. 30, no. 13, pp. 1415–1421, 2012. View at Publisher · View at Google Scholar · View at Scopus
  43. A. Giraldo, J. Talavera, M. J. Fernandez-Del-Palacio et al., “Percutaneous intramyocardial injection of amniotic membrane-derived mesenchymal stem cells improves ventricular function and survival in non-ischaemic cardiomyopathy in rabbits,” European Heart Journal, vol. 36, p. 149, 2015. View at Google Scholar